Cyclic GMP-specific phosphodiesterase inhibitors

Details Cyclic GMP-specific phosphodiesterase inhibitors Cyclic GMP-specific phosphodiesterase inhibitors

2002-12-04

2004-11-30

Raymond, Richard L. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S342000

Reexamination Certificate

active

06825197

ABSTRACT:

FIELD AND BACKGROUND OF THE INVENTION
This invention relates to a series of compounds, to methods of preparing the compounds, to pharmaceutical compositions containing the compounds, and to their use as therapeutic agents. In particular, the invention relates to compounds that are potent and selective inhibitors of cyclic guanosine 3′,5′-monophosphate specific phosphodiesterase (cGMP-specific PDE), in particular PDE5, and have utility in a variety of therapeutic areas wherein such inhibition is considered beneficial, including the treatment of cardiovascular disorders and erectile dysfunction.


REFERENCES:
patent: 57-11984 (1982-01-01), None
patent: WO 95/19978 (1995-07-01), None
patent: WO 96/32003 (1996-10-01), None
patent: WO 97/03985 (1997-02-01), None
patent: WO 97/43287 (1997-11-01), None
patent: WO 00/15639 (2000-03-01), None
Cialis ® Prescribing Information, Eli Lilly and Company, Indianapolis, IN 46285, U.S.A. (2003).*
Karsten et al, “Involvement of cyclic nucleotides in renal artery smooth muscle relaxation” Urology Research, vol. 30, pp. 36 373 (2003).*
Fritz et al, “Stimulation of the Nitric Oxide-Guanosine 3′,5′-Cyclic Monophoshate Pathway by Sildenafil: Effect on Rectal Muscle Tone, Distensibility, and Perception in Health and in Irrittable Bowel Syndrome” Am. J. Gastroenterology, vol. 98(10), pp. 2253-2260. (2003).*
Kaplan et al, “Safety and Efficacy of Sildenafil in Postmenopausal Women with Sexual Dysfunction” Urology, vol. 53(3), pp. 481-486 (1999).*
Berman, M.D. and Goldstein, M.D. Letters to the editor, Urology, vol. 54(3), pp. 578-579, (1999).*
Word and Cornwell, “Regulation of cGMP-induced relaxation and cGMP-dependent protein kinase in rat myometrium during pregnancy” Am. J. Physiol. 274 (Cell Physiol. 43), pp. C748-C756, (1998).*
Perry and Higgs, “Chemotherapeutic potential of phosphodiesterase inhibitors” Current Opinion in Chemical Biology, vol. 2, pp. 472-481 (1998).*
Willette et al, “Identification, Characterization, and Functional Role of Phosphodiesterase Type IV in Cerebral Vessels: Effects Selective Phosphodiesterase Inhibitors” J. Cerebral Blood Flow and Metabolism, vol. 17, pp. 210-219 (1997).*
Sybertz and Czarnieki, “Inhibitors of PDE1 and PDE5 cGMP phosphodiesterases: patents and therapeutic potential” Expert Opinion on Therapeutic Patents, vol. 7(6), pp. 631-639 (1997).
Madrigal et al, “Stereochemical issues related to the synthesis of 7,10,16,16a-tetrahydro-11H-quinazolino-[2′,3′,:3,4]pyrazino[1,2-b]-&bgr;-carboline-5,8-diones” Tetrahedron: Asymmetry, vol. 9(17), pp. 3115-3123 (1998). cas online abstract.
M.F. Braña et al.,Synthetic Communications, 20(12), 1793-1810 (1990).
M.F. Braña et al.,J. Heterocyclic Chem., 27, 703 (1990).
M.F. Braña et al.,J. Heterocyclic Chem., 31, 1235 (1994).

Affiliated with

Also associated with

Rating

Cyclic GMP-specific phosphodiesterase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cyclic GMP-specific phosphodiesterase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic GMP-specific phosphodiesterase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3293493